Nelli Westercamp

ORCID, self-asserted

ORCID 0000-0003-0136-9750

Publications

Citations

300

h-index

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

Publications

7 works in the graph, newest first.

Impact of introducing RTS,S/AS01E malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme
2026The LancetJournalOpen access3 citations10.1016/s0140-6736(26)00248-5
Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial
2025The Lancet Global HealthJournalOpen access3 citations10.1016/s2214-109x(25)00272-4
Value profile for Malaria vaccines and monoclonal antibodies
2025VaccineJournalOpen access3 citations10.1016/j.vaccine.2025.127971
Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi
2024The LancetJournalOpen access89 citations10.1016/s0140-6736(24)00004-7
Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial
2024The Lancet Infectious DiseasesJournalOpen access17 citations10.1016/s1473-3099(24)00179-8
Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine
2024The Journal of Infectious DiseasesJournalOpen accessFirst authorCorresponding4 citations10.1093/infdis/jiae075
Efficacy of RTS,S/AS01E malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5–17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial
2022The Lancet Infectious DiseasesJournalOpen access75 citations10.1016/s1473-3099(22)00273-0